CubaHeal Research At the National Extension Workshop conference carried on September 27th, 2017 in the province of Camagüey, doctors from the provinces of Cienfuegos and Sancti Spíritus presented their evidence and application results on the effectiveness of the use of Heberferon for the treatment of Gorlin Syndrome. Gorlin Syndrome, also known as Nevoid Basal-Cell Carcinoma...
AllCardiovascularChild DevelopmentCuba’s AchievementsCubaHeal NewsDermatologyEducationEndocrinologyGeriatricGynecologyInternational CollaborationMedical (General)NeurologyOncologyOphthalmologyOrthopedicPsychiatrySubstance Abuse RehabilitationTravel InsuranceUncategorized
A new hope for skin cancer patients in Cuba. Skin cancer is a disease which affects the skin due to irregular and harmful formation of skin cells. It can spread to other parts of the human body if not treated in time. The three types of skin cancer found across the world are as follows:...
Racotumomab (trade name Vaxira) is a non-small cell lung cancer (NSCLC) vaccine developed by researchers at the Center of Molecular Immunology, Cuba in collaboration with researchers from the Buenos Aires University, Argentina with promising results. It was granted certificate of approval by the State Center for Quality Control of Medicines of Cuba and by January,...
Cimavax-EGF for Non-small Cell Lung Cancer Vaccine Cimavax-EGF is the first worldwide registered therapeutic vaccine for non-small lung cancer developed in Cuba by the Center for Molecular Immunology in conjunction with the Center for Genetic Engineering and Biotechnology. In 2008 it was approved by the Cuban regulatory authority for the use in adults with advanced...
The recommended dose of CIMAher® is 200 mg given once a week for 6 weeks concomitant with radiotherapy and / or radio-chemotherapy. Subsequently, dose of 200 mg every 15 days (maintenance dose) until the general condition of the patient allows it.